PMID: 7546208Sep 1, 1995Paper

Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells

Immunology Today
Y Reisner, M F Martelli

Abstract

Throughout the 1970s, graft-versus-host disease (GVHD) was uniformly lethal in recipients of HLA-mismatched bone marrow. This major obstacle was overcome in 1980 by the introduction of rigorous T-cell depletion prior to transplantation into patients with severe combined immunodeficiency. However, in leukemia patients, the benefit of preventing GVHD was offset by graft rejection or graft failure. In this article, Yair Reisner and Massimo Martelli discuss how this problem may be overcome by intensification of the conditioning protocol in conjunction with a major increase in the dose of transplanted stem cells.

References

Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·T LapidotY Reisner
Jun 28, 1986·Lancet·R P Gale, Y Reisner
Feb 7, 1981·Lancet·P N TrewbyR S Elkeles
Apr 1, 1983·Canadian Journal of Physiology and Pharmacology·J D McCullyN L Morrison
Jun 5, 1993·Lancet·S C Arya
Jul 31, 2002·Applied and Environmental Microbiology·Silke BlümelAndreas Stolz
Oct 26, 2010·Molecular Cancer Therapeutics·Chad A DumstorfJeremy R Graff

❮ Previous
Next ❯

Citations

Apr 29, 1998·Stem Cells·K SugiuraS Ikehara
Sep 30, 2000·Stem Cells·L KanzS Scheding
Sep 21, 2004·Springer Seminars in Immunopathology·Franco Aversa, Massimo F Martelli
Oct 6, 2007·Immunologic Research·Yair Reisner
Oct 1, 1995·Current Opinion in Immunology·Y Reisner, H Segall
Feb 1, 1997·Transplantation Proceedings·C RicordiA G Tzakis
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·C AristeiP Latini
Apr 25, 2003·Critical Reviews in Oncology/hematology·Shimon SlavinReuven Or
Dec 24, 2002·Comptes rendus biologies·Marina Cavazzana-CalvoAlain Fischer
Aug 7, 2001·Reviews in Clinical and Experimental Hematology·F AversaM F Martelli
Jan 19, 2002·Seminars in Hematology·Massimo F MartelliYair Reisner
Mar 13, 1999·The New England Journal of Medicine·T H Eiermann
Oct 19, 2000·Journal of Pediatric Hematology/oncology·J KapelushnikA Nagler
Jan 27, 2007·Current Opinion in Hematology·Tsila Zuckerman, Jacob M Rowe
Jun 18, 1999·Annals of the New York Academy of Sciences·R HandgretingerT Klingebiel
Feb 19, 2005·International Journal of Hematology·Loredana RuggeriAndrea Velardi
Nov 10, 2010·The Review of Diabetic Studies : RDS·Carmen FotinoAntonello Pileggi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.